Abstract
Background – Atopic dermatitis (AD) is a common inflammatory skin disease of dogs. Interleukin 34 (IL34) is a monocyte/macrophage growth factor, produced mainly by keratinocytes, that has been implicated in several human inflammatory conditions including human AD.
Hypothesis – Canine serum IL34 concentrations are increased in dogs with AD and correlate with clinical lesion and pruritus scores.
Animals – 47 client owned dogs diagnosed with AD and 25 healthy, unaffected control dogs.
Methods – A commercially available IL34 ELISA was optimised for the measurement of IL34 in canine serum samples. Information regarding treatment, clinical lesion scores (CADESI-4) and pruritus (pVAS) were recorded for each dog at the time of serum collection.
Results – Dogs with AD had significantly increased serum IL34 concentrations compared to controls. There was a significant positive correlation between IL34 concentrations and CADESI-4 and pVAS scores. Concentrations of IL34 remained increased in dogs with AD receiving steroids or the JAK1 inhibitor, oclacitinib, compared to unaffected control dogs.
Conclusions and clinical importance – Serum IL34 concentrations are increased in dogs with AD and are correlated with clinical severity and pruritus. IL34 may be a suitable candidate therapeutic target for canine AD
Hypothesis – Canine serum IL34 concentrations are increased in dogs with AD and correlate with clinical lesion and pruritus scores.
Animals – 47 client owned dogs diagnosed with AD and 25 healthy, unaffected control dogs.
Methods – A commercially available IL34 ELISA was optimised for the measurement of IL34 in canine serum samples. Information regarding treatment, clinical lesion scores (CADESI-4) and pruritus (pVAS) were recorded for each dog at the time of serum collection.
Results – Dogs with AD had significantly increased serum IL34 concentrations compared to controls. There was a significant positive correlation between IL34 concentrations and CADESI-4 and pVAS scores. Concentrations of IL34 remained increased in dogs with AD receiving steroids or the JAK1 inhibitor, oclacitinib, compared to unaffected control dogs.
Conclusions and clinical importance – Serum IL34 concentrations are increased in dogs with AD and are correlated with clinical severity and pruritus. IL34 may be a suitable candidate therapeutic target for canine AD
| Original language | English |
|---|---|
| Pages (from-to) | 359-e94 |
| Journal | Veterinary Dermatology |
| Volume | 31 |
| Early online date | 13 Aug 2020 |
| DOIs | |
| Publication status | Published - 29 Sept 2020 |